Another red flag in Alphaeon’s PR in #msg-121755626: There is no mention of the intention to submit a BLA, as you would expect in a PR announcing purportedly positive phase-3 data.
My supposition is that there is no plan for a US BLA or European MAA for DWP-450 and that the product is intended for commercialization in emerging markets, where it can compete on price with various low-quality botulinum toxins.
Bottom line: If anybody sold RVNC last week because of Alphaeon’s PR, they probably made a mistake.
Market Data 
Markets 
AI
